If you have been NEWLY DIAGNOSED START HERE
On August 20, 2016, in collaboration with the University of Colorado Cancer Center, GRACE presented the Targeted Therapies in Lung Cancer Patient Forum in Aurora Colorado. We are happy to share the videos from this live and webcast forum. Our second video is the first part of the forum breakout session for ALK + patients and caregivers, featuring Dr. Shirish Gadgeel and patient moderator Linnea Olson.
On August 20, 2016, in collaboration with the University of Colorado Cancer Center, GRACE presented the Targeted Therapies in Lung Cancer Patient Forum in Aurora Colorado. We are happy to share the videos from this live and webcast forum. Our first video welcomes all to the event, and it was our extreme pleasure to have Chris Draft and Dr. Ross Camidge join us to start the day! This is followed by keynote topic "Does NED matter? Using “curative” surgery or radiation techniques to treat "incurable" advanced lung cancer," with Dr. Rob Meguid, and a panel discussion featuring Dr. Meguid, Dr. Chad Rusthoven, Dr. Ross Camidge, and chaired by Dr. H. Jack West.
For our third video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD, Medical Oncologist, Thoracic Oncology Program, Hospital General Universitario, Gregorio Marraron, Madrid, Spain joined GRACE to discuss how NSCLC subtype (histology) can alter chemotherapy recommendations in advanced NSCLC.
For our second video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD, Medical Oncologist, Thoracic Oncology Program, Hospital General Universitario, Gregorio Marraron, Madrid, Spain joined GRACE to discuss what is the value of chemotherapy in advanced/metastatic NSCLC.
All of us at the Global Resource for Advancing Cancer Education are very excited to introduce our newest project - the GRACE Spanish Lung Cancer Library. This collection of videos with our Spanish speaking faculty will discuss the basics of lung cancer for Spanish speaking patients and caregivers. For our first video, Antonio Calles, MD, Medical Oncologist, Thoracic Oncology Program, Hospital General Universitario, Gregorio Marraron, Madrid, Spain joined GRACE to discuss what is adjuvant chemotherapy for early stage NSCLC and why it would be recommended.
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC discusses the feasibility of molecular marker testing and targeted therapy in the adjuvant or post-operative setting.
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC discusses the feasibility of molecular marker testing and targeted therapy in the adjuvant or post-operative setting.
Are there things that physicians and patients can do to make the decision making process easier for lung cancer patients in some way? The survey takes approximately 15 minutes or less to complete.
Are there things that physicians and patients can do to make the decision making process easier for lung cancer patients in some way? The survey takes approximately 15 minutes or less to complete.
Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center reviews early trial data of immunotherapy agents for treatment of small cell lung cancer (SCLC).
We are here and the team is working to get everything in order, including the forums. Thanks for your patience, it's going to be awesome! aka...
I have been in Xalkori for 2 months, A current CT scans shows the Stage 4 NSCLC (ROS1) is stable. An EKG shows a higher QTc (596) since the last EKG 4...
I have been in Xalkori for 2 months, A current CT scans shows the Stage 4 NSCLC (ROS1) is stable. An EKG shows a higher QTc (596) since the last EKG 4...
Hello Friends — We are scheduled to go live with our new GRACE site on September 4 around 3 pm, barring no showstoppers. The majority of your accounts...
Memorial Sloan-Kettering Cancer Center medical oncologist Dr. Greg Riely explains how testing for specific mutations in patients with advanced NSCLC can guide prognosis and treatment recommendations.
After having had further discussions with colleagues about the data and the challenges in interpreting the optimal treatment in this setting, I am inclined to soften my view that Taxotere is quite likely to be the superior second line therapy for most patients...
Dr. Vivek Mehta, radiation oncologist, reviews the basic principles and treatment approach for limited stage small cell lung cancer, which combines chest radiation with concurrent chemotherapy.
Why radiate a perfectly good brain? Dr. Vivek Mehta, radiation oncologist, discusses the possible role for prophylactic cranial irradiation (PCI) for extensive stage small cell lung cancer (SCLC) to decrease risk of brain metastases and improve survival.
Dear GRACE Community Members - My father was diagnosed with stage 3 NSCLC in Dec 2012. At the time of diagnosis, he had tumors in both lungs and in the lymph nodes.
He has taken almost 40 rounds of chemotherapy until a lack of response to the drugs and high toxicity occurred.
He started taking Opdivo in July 2015 and stopped it after 3 rounds due to Pneumonia in August 2015. He was hospitalized for 8 days but was able to overcome it and was discharged home. He has not taken any cancer drugs since (including opdivo).
In the span of a week, we’ve just had new FDA approvals of Keytruda (pembrolizumab) for previously treated advanced non-small cell lung cancer (NSCLC) patients with tumors that express PD-L1, followed by a broadened approval for Opdivo (nivolumab) for previously...
Radiation to the brain is a component of our treatment of limited stage small cell lung cancer, even with no evidence of cancer there. Dr. Vivek Mehta, radiation oncologist, reviews why we would do such a thing.
Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.
The concept of maintenance therapy for advanced lung cancer has emerged over the past few years. Dr. Jack West, medical oncologist, reviews the concepts behind it and treatment options for patients.
Bronchioloalveolar carcinoma (BAC) is an unusual subtype of lung cancer; medical oncologist Dr. Jack West reviews the evidence on the best systemic therapy to treat advanced, multifocal BAC.
Copyright © 2021 Global Resource for Advancing Cancer Education
Site by Freelock